Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients
Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A
Published in Gynecological Endocrinology
Abstract
Clinical trial showing myo-inositol 4g daily restored spontaneous ovulation in PCOS patients with comparable efficacy to clomiphene citrate but superior safety profile and improved oocyte quality.
Methodology
Prospective clinical trial in women with PCOS comparing myo-inositol plus folic acid alone versus myo-inositol combined with clomiphene citrate; ovulation confirmed by ultrasound and progesterone monitoring.
Key Findings
Myo-inositol (4 g/day with folic acid) restored spontaneous ovulation in a substantial proportion of women with PCOS; adding clomiphene citrate increased ovulation rates further. Myo-inositol alone was associated with better oocyte and endometrial quality and no anti-oestrogenic effects.
Conclusions
Myo-inositol is a reasonable first-line insulin-sensitising option for ovulation induction in PCOS, either alone or as an adjunct to clomiphene citrate, with a favourable tolerability profile.
Limitations
Small single-centre open study, short follow-up, no placebo arm, and live-birth outcomes were not the primary endpoint.
Supplements Studied
Myo-inositol alone and with clomiphene citrate restored ovulation in polycystic ovary syndrome patients.
Outcomes Measured
Clinical trial showing myo-inositol 4g daily restored spontaneous ovulation in PCOS patients with comparable efficacy to clomiphene citrate but superior safety profile and improved oocyte quality.
Myo-inositol restored ovulation alone and in combination with clomiphene citrate.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not clearly reported; investigators have declared relationships with inositol manufacturers
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.